DEA Targets Three New Mitragynine Compounds for Schedule I
Published Date: 7/6/2026
Proposed Rule
Summary
Starting July 6, 2026, the DEA plans to temporarily put three substances related to 7-hydroxymitragynine—Mitragynine Pseudoindoxyl, MGM-15, and MGM-16—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move aims to control these substances quickly while the DEA studies them further, affecting businesses and researchers handling these compounds.
Analyzed Economic Effects
4 provisions identified: 0 benefits, 4 costs, 0 mixed.
Possession Becomes a Schedule I Offense
If you possess mitragynine pseudoindoxyl, MGM-15, or MGM-16 after the temporary order is published, you will be subject to Schedule I rules and the CSA's civil and criminal penalties. The temporary order will take effect on the date it is published in the Federal Register (to be published on or after August 5, 2026) and impose schedule I controls.
Researchers Face Schedule I Requirements
If you conduct research, instructional activities, or chemical analysis with mitragynine pseudoindoxyl, MGM-15, or MGM-16, those activities will be subject to Schedule I regulatory controls and associated administrative requirements and sanctions once the temporary order is published. The temporary order will take effect on its publication date (on or after August 5, 2026).
Retailers and Vendors Lose Legal Market Access
Retailers, online vendors, vape shops, gas stations, and other sellers of products containing these chemicals will be subject to Schedule I prohibitions on manufacture and distribution when the temporary order is published. Selling or distributing these substances will trigger the CSA's criminal and civil sanctions.
Temporary Scheduling Period Set (2 + 1 Years)
The temporary placement of mitragynine pseudoindoxyl, MGM-15, and MGM-16 in Schedule I will remain in effect for two years from the order's publication date, with a possible one-year extension if regular scheduling proceedings are initiated. The DEA intends to publish the temporary scheduling order on or after August 5, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2026-13580, Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put 7-hydroxymitragynine above a certain amount into Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just has this substance, bringing strict rules and penalties. The move aims to keep people safe while the government figures out the long-term plan.
Next: 2026-13586, Registering NFA Firearms That Fall Out of Government Contract
If you make special firearms for the U.S. Government and your contract ends, you’ll now have a new way to register those guns even if you missed the usual deadline. This change helps manufacturers avoid penalties and keeps everything clear and fair. Comments on this proposal are open until September 4, 2026, so don’t miss your chance to weigh in!